Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedicalCV AtriLaze 1064nm laser:

This article was originally published in Clinica

Executive Summary

The US FDA has given MedicalCV 510(k) market clearance to expand the functionality of its AtriLaze surgical ablation system for treating atrial fibrillation (AF), by allowing the device to deliver 1064nm wavelength laser energy. The system is already cleared for the delivery of 810nm laser light. The new wavelength optimises the application of laser energy to cardiac tissue and is particularly suitable for the miniaturisation required to use laser technology through smaller access ports said MedicalCV. This brings the firm a significant step closer to delivering a "truly stand-alone, minimally invasive" AF therapy procedure, the Inver Grove Heights, Minnesota company added.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051570

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel